NextCell Pharma publishes Interim Report 3 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Third quarter (2022-03-01 until 2022-05-31)
● Operating income amounted to 1 636 (906) TSEK.
● Operating result amounted to -9 307(-6 457) TSEK.
● Earnings per share* amounted to -0,27 (-0,19) SEK.
● Cash and bank amounted to 107 054 (150 754) TSEK.
● Solidity** amounted to 93,5 (96,9) %.
First nine months (2021-09-01 till 2022-05-31)
● Operating income amounted to 4 824 (3 074) TSEK.
● Operating result amounted to -25 991 (-20 079) TSEK.
● Earnings per share* amounted to -0,22 (-0,69) SEK.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523 (34,056,943) shares. Average number of shares for the first nine months 2021/2022: 34,379,523 (29,074,754) shares. Number of shares in NextCell as of May 31, 2022: 34,379,523 (34,379,523) shares.
**Solidity: Own capital's share of the sheet total
Significant events in the third quarter
● NextCell announced in early April that the stem cell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in cellovia's biobank, suffers from a serious blood disorder to be treated with stem cells at the Hematology Department at Rigshospitalet.
● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years
● NextCell announced at the end of April that it is participating in a conference for world-leading cell therapies, the International Society for Cell and Gene Therapy 2022, in San Francisco and is represented by Mathias Svahn, CEO. Dr Svahn is a member of the Business Development and Finance Committee of ISCT.
● NextCell announced at the end of May that the company is presenting the ongoing clinical trial program with the drug candidate ProTrans lead cell therapy at the Advanced Therapies Congress in London on May 24-25.
● NextCell announced at the end of May that the European Patent Office(EPO) had issued an advance grant notice of the patent entitled "Allogeneic Composition" (publication number EP3752598). The patent describes the method of manufacturing the drugcandidate ProTrans and where the selection algorithm for selecting optimal cells and donors is the core. Patent protection is valid up to and i 2039.
Significant events after the reporting period
● NextCell announced in early June that all six children in the first part of the study with ProTrans. Patients will be monitored during the summer after which the safety of the treatment will be evaluated by an independent safety committee
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-07-2022 07:30 CET.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.
About NextCell Pharma AB
NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 10% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).